HK1029754A1 - Formulations for protection of peg-interferon alpha conjugates. - Google Patents

Formulations for protection of peg-interferon alpha conjugates.

Info

Publication number
HK1029754A1
HK1029754A1 HK01100376A HK01100376A HK1029754A1 HK 1029754 A1 HK1029754 A1 HK 1029754A1 HK 01100376 A HK01100376 A HK 01100376A HK 01100376 A HK01100376 A HK 01100376A HK 1029754 A1 HK1029754 A1 HK 1029754A1
Authority
HK
Hong Kong
Prior art keywords
peg
formulations
protection
interferon alpha
alpha conjugates
Prior art date
Application number
HK01100376A
Other languages
English (en)
Inventor
Douglas F Kline
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21957085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1029754(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1029754A1 publication Critical patent/HK1029754A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
HK01100376A 1998-03-26 2001-01-13 Formulations for protection of peg-interferon alpha conjugates. HK1029754A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4890798A 1998-03-26 1998-03-26
PCT/US1999/004268 WO1999048535A1 (en) 1998-03-26 1999-03-24 Formulations for protection of peg-interferon alpha conjugates

Publications (1)

Publication Number Publication Date
HK1029754A1 true HK1029754A1 (en) 2001-04-12

Family

ID=21957085

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01100376A HK1029754A1 (en) 1998-03-26 2001-01-13 Formulations for protection of peg-interferon alpha conjugates.

Country Status (26)

Country Link
EP (1) EP1066059B1 (es)
JP (3) JP3643034B2 (es)
KR (1) KR100420642B1 (es)
CN (1) CN1191863C (es)
AR (1) AR014772A1 (es)
AT (1) ATE297761T1 (es)
AU (1) AU754002B2 (es)
BR (1) BR9909087A (es)
CA (1) CA2324467C (es)
CO (1) CO5080738A1 (es)
CZ (1) CZ302005B6 (es)
DE (1) DE69925820T2 (es)
ES (1) ES2241272T3 (es)
HK (1) HK1029754A1 (es)
HU (1) HU228877B1 (es)
ID (1) ID28470A (es)
IL (2) IL138221A0 (es)
MY (1) MY119227A (es)
NO (1) NO329916B1 (es)
NZ (1) NZ506631A (es)
PE (1) PE20000338A1 (es)
PL (1) PL193286B1 (es)
PT (1) PT1066059E (es)
SK (1) SK285284B6 (es)
TW (2) TWI243057B (es)
WO (1) WO1999048535A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9909087A (pt) * 1998-03-26 2000-12-05 Schering Corp Formulações para proteção de conjugados peg-alfa interferon
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
JP3712914B2 (ja) * 1999-04-08 2005-11-02 シェーリング コーポレイション 腎細胞ガン処置
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
CA2397793A1 (en) * 2000-01-24 2001-07-26 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
KR100353392B1 (ko) * 2000-03-13 2002-09-18 선바이오(주) 높은 생체 활성도를 갖는 생체 활성 단백질과 peg의결합체 제조방법
AU2001244713A1 (en) 2000-04-03 2001-10-15 Santen Pharmaceutical Co. Ltd. Transporters and drug delivery system by using the same
PL205936B1 (pl) 2002-02-22 2010-06-30 Schering Corp Farmaceutyczny preparat zawierający termozolomid oraz sposób jego wytwarzania
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
CN101039660B (zh) * 2004-08-12 2010-10-06 先灵公司 稳定的聚乙二醇化干扰素制剂
RS52417B (en) 2007-12-20 2013-02-28 Merck Serono S.A. PEG-INTERFERON-BETA FORMULATIONS
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR20150074167A (ko) * 2012-10-26 2015-07-01 루핀 리미티드 Peg 인터페론 알파-2b의 안정한 약학 조성물
KR101736870B1 (ko) * 2014-08-20 2017-05-18 한국코러스 주식회사 인터페론 접합체를 포함하는 복합체 및 이의 제조방법
SI3463308T1 (sl) 2016-06-01 2022-04-29 Servier IP UK Limited Formulacije polialkilenoksidne asparaginaze in postopki za pripravo in uporabo le-teh
CN112358541B (zh) * 2020-11-25 2022-04-01 广州迪澳医疗科技有限公司 一种重组人γ-干扰素的冻干保护剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2024046A1 (en) * 1989-09-28 1991-03-29 Alberto Ferro Stabilized leukocyte-interferons
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ES2174915T3 (es) * 1993-11-10 2002-11-16 Enzon Inc Productos de conjugacion mejorados de un interferon con un polimero.
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
CN1151842C (zh) * 1995-07-27 2004-06-02 基因技术股份有限公司 稳定等渗的冻干蛋白制剂
EP0858343B1 (en) * 1995-11-02 2004-03-31 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
BR9909087A (pt) * 1998-03-26 2000-12-05 Schering Corp Formulações para proteção de conjugados peg-alfa interferon

Also Published As

Publication number Publication date
JP2002507583A (ja) 2002-03-12
JP2003221345A (ja) 2003-08-05
JP4580744B2 (ja) 2010-11-17
IL138221A (en) 2007-12-03
ATE297761T1 (de) 2005-07-15
ES2241272T3 (es) 2005-10-16
HUP0101749A2 (hu) 2001-11-28
BR9909087A (pt) 2000-12-05
MY119227A (en) 2005-04-30
NO20004785D0 (no) 2000-09-25
CZ302005B6 (cs) 2010-09-01
TWI243057B (en) 2005-11-11
AU3181299A (en) 1999-10-18
HUP0101749A3 (en) 2001-12-28
IL138221A0 (en) 2001-10-31
EP1066059B1 (en) 2005-06-15
NZ506631A (en) 2003-03-28
NO329916B1 (no) 2011-01-24
TWI250024B (en) 2006-03-01
PL193286B1 (pl) 2007-01-31
CA2324467A1 (en) 1999-09-30
NO20004785L (no) 2000-09-25
PE20000338A1 (es) 2000-05-16
ID28470A (id) 2001-05-24
TW200536557A (en) 2005-11-16
PL345568A1 (en) 2001-12-17
SK14262000A3 (sk) 2001-04-09
PT1066059E (pt) 2005-10-31
CN1191863C (zh) 2005-03-09
KR20010034654A (ko) 2001-04-25
CA2324467C (en) 2002-11-05
DE69925820T2 (de) 2006-05-18
HU228877B1 (en) 2013-06-28
DE69925820D1 (de) 2005-07-21
JP2005104985A (ja) 2005-04-21
JP3643034B2 (ja) 2005-04-27
KR100420642B1 (ko) 2004-03-02
CZ20003315A3 (cs) 2001-04-11
CN1295484A (zh) 2001-05-16
WO1999048535A1 (en) 1999-09-30
SK285284B6 (sk) 2006-10-05
CO5080738A1 (es) 2001-09-25
AR014772A1 (es) 2001-03-28
AU754002B2 (en) 2002-10-31
EP1066059A1 (en) 2001-01-10

Similar Documents

Publication Publication Date Title
SG79255A1 (en) Pharmaceutical formulations
GB9804013D0 (en) Formulations
SG77243A1 (en) Ziprasidone formulations
IL137998A0 (en) Combined vaccine compositions
HUP0103507A3 (en) Pharmaceutical compositions comprising 2-quinolones
GB9827996D0 (en) Pharmaceutical Compositions
HK1029754A1 (en) Formulations for protection of peg-interferon alpha conjugates.
PL343627A1 (en) Medicinal compositions
GB9809213D0 (en) Pharmaceutical compositions
GB9806312D0 (en) Novel formulations
AP2000001878A0 (en) Pharmaceutical compositions
GB9815002D0 (en) Formulations
GB9815001D0 (en) Formulations
GB9806487D0 (en) Pharmaceutical compositions
GB9810181D0 (en) Novel formulations
GB9826392D0 (en) Pharmaceutical formulations
GB9816558D0 (en) Pharmaceutical formulations
GB9825117D0 (en) Pharmaceutical formulations
GB9807556D0 (en) Pharmaceutical formulations
GB9820837D0 (en) Pharmaceutical formulations
GB9817429D0 (en) Pharmaceutical formulations
GB9828205D0 (en) Pharmaceutical formulations
GB9823192D0 (en) Pharmaceutical formulations
GB9805931D0 (en) Pharmaceutical formulations
GB9813452D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PE Patent expired

Effective date: 20190323